© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Expert Interviews
Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health
Phase 3 PEACHTREE, AZALEA integrated study results presented at ARVO 2022: BCVA gains, CST reduction with Xipere
May 12, 2022
The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
Use of CO-02 to stimulate the trigeminal nerve is a reasonable mechanism to help treat dry eyes
May 11, 2022
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
New advancements in IOL technology is exciting for presbyopia treatment
May 11, 2022
Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.
ARMOR study evaluates antibiotic resistance in the treatment of staph infections
May 11, 2022
Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."
Study evaluates OC-01 (varenicline solution) as a treatment for symptoms and signs of dry eye
May 11, 2022
Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.
Cell therapy trial shows promising results for patients with advanced dry AMD
May 10, 2022
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).
New PRO instrument helps measure patient experience with therapies such as anti-VEGF agents, lasers to treat their eye disease
May 09, 2022
Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.
Why are ophthalmology residents choosing to not pursue neuro-op?
May 07, 2022
There is a shortage of neuro-opthalmologists in the US, and Andy Lee, MD, and Elizabeth Fortin, MD, look at recent survey results diving into this topic.
Dexamethasone plug opens opportunity for treatment that will bring patients relief, help alleviate and mitigate the signs and symptoms associated with conjunctivitis from allergies
May 06, 2022
A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.
New noninvasive technology shows positive safety and efficacy for the treatment of open angle glaucoma
May 05, 2022
Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.